EGFR and non-small cell lung carcinoma: Determining the status of EGFR and KRAS mutations is crucial for guiding treatment in NSCLC patients receiving EGFR tyrosine kinase inhibitors and colorectal cancer patients treated with anti-EGFR therapy respectively.